Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
lol no way they have alot of value in there product and pattens and litle to no debt and cash short means nothing in the pink world ,money is always availble when you have many products such as they do. Do you or did you own shares in EAPH earnestdd??
Yes the float is so small and this could move up alot on some good news
DD shows new managment a money guy and a desire to go forward with sales of many of there products
eaph will rise again simple DD shows that
EAPH may have a Big future,Any selling all depends on the news going forward at one time The news was this was going to be a Big CASH COW "see the old news story below" If they get it right this time the skys the limit:)
July 22, 2011 06:00 ET
Easton Pharmaceuticals Announces Projections of $15 Million in Revenue For 2012 From The Company's First Territory Launch of VIORRA in Mexico
VIORRA is a Female Over-The-Counter Aid for Treatment to Restore and Improve Vaginal Moisture and Elasticity Plus Increase Sexual Desire
TORONTO, ONTARIO--(Marketwire - July 22, 2011) - Easton Pharmaceuticals (OTC:EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products has been advised of by BMV Medica S.A. de C.V. (BMV), the company that was recently retained in Mexico to finalize regulatory approval and arrange distribution partnerships for the company's first product launch in Mexico;
•BMV Medica S.A. de C.V. (BMV) has advised that their initial market analysis and conversations with distribution partnerships for the company's first product launch, VIORRA an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity, that also exhibits a very positive effect on women's sexual desire and arousal FSAD (Female Sexual Arousal Disorder) could generate upwards of $15 million dollars in revenue within twelve months of product launch.
•Mexico represents an ideal first territory launch site for our VIORRA Female Sexual Dysfunction (FSAD) product, stated John Easton, CEO and Chairman of the board of Easton Pharmaceuticals, "As Male Sexual Dysfunction products have historically done very well in Mexico, and with a population of 120 million, the raw numbers of prospective female customers are very attractive to Easton Pharmaceuticals. The world market for these female conditions are estimated in excess of $2 billion."
•BMV estimates the regulatory approval process will be completed in early 2012. In parallel with the regulatory filing, Easton Pharmaceuticals under the guidance of BMV has begun talks with several large distribution companies that are focused on sales and marketing in the women's health market. Easton Pharmaceuticals" believes that with both the regulatory and commercial alliance initiatives running in parallel will enable a timely, successful launch of VIORRA and generate upwards of $15 million annual company revenue from Mexico beginning in 2012.
When news comes and this gets picked up by new buyers we will go multi penny in the same day
Yes any news will send this up to penny land fast
EAPH up nice on the open on low volume
someone please post a lev 2 quote please I will be buying more ;)
Hard to get shares even at the ask
what will the next news story be?? wow
I need in can anyone pot lev 2 page??? please
WRONG AGAIN the facts are on there website ViorraTM has completed and passed irritation, allergic reaction, oral toxicity and three year stability studies. ViorraTM has completed an Open Label Clinical Pilot Trial to evaluate the safety and efficacy of the product. Pre and post-menopausal women with pre-diagnosed sexual function disorder for the past five years tested ViorraTM. There were no adverse data reported during the study and collectively the subjects reported: Less genital pain during intercourse, more sexual attempts with their partner, increase in vaginal lubrication, higher incidence of orgasm, increased desire to engage in sexual activity and an overall increase in sexual satisfaction
WRONG. FDA GAVE THEM THE GO AHEAD AND THATS IN THERE FILING
Trials and test have been done already do some dd
anytime now hours days weeks hard to tell but the all new managemnt that took over have GREAT history and backgrounds and they are all shareholder with alot to gain EAPH has no history of dumping shares only paying for some services with small ammounts of shares
Keep a eye/watch on EAPH low float and waiting on Big news this will fly on little volume check out te past news and do some DD ithis will be a big money maker for sure
Keep a eye/watch on EAPH low float and waiting on Big news this will fly on little volume check out the past news as well
Keep a eye/watch on EAPH low float and waiting on Big news this will fly on little volume
The changes were to preserve a longer shelf life of the product
LOL what are you talking about NO viability lol please explain that one lol?????
Read the last news out its said" Easton Pharmaceuticals Announces Three New Additional Products & a Revision to Its Viorra Flagship Product "
lolololol New managment and revived product is where you start lollololo
post some of the dd you have done everythng you post is the opisit of the facts in the press releases
You also dont need alot of funds if you work with a 3rd party make market and distribute However you will make less profit
Easton Pharmaceuticals, Inc. (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, today announced its initiatives to enter into the Medical Marijuana Sector in both the U.S. and Canadian Markets.
As the company searches for new avenues to generate revenues and enhance its business model, Easton Pharmaceuticals, Inc. is retaining the services of a third party consultants to assist the company with submitting applications with the intent of opening small boutique clinics in both the Canadian and American markets which includes various provinces and states starting in Michigan and California, two marijuana "friendly" states for medicinal marijuana.
Michigan created a Medical Marijuana Program (MMMP), a state registry program where state law provides protections for the medical use of marijuana and allows participants to legally possess, use, buy and grow medical marijuana as will various Provinces in Canada once a national law presently being reviewed is passed.
Easton intends on using the services of qualified third parties to obtain licenses and assist with the setting up of a highly regulated and controlled small clinic with the to supply patients who have obtained a valid medical prescription. Such clinics would need to be strictly inspected on a regular basis in order that it meets all government standards. Easton and others in the industry are awaiting regulations and the approval by both the Canadian and United States governments, but is in the application process in certain states and provinces. Easton Pharmaceuticals is also in the process of developing other OTC herbal products specifically designed for this sector.
Although “Viorra” and other products possessing Easton’s reformulated transdermal delivery system is and will continue to be the main focus for the company and it’s initiatives, Easton Pharmaceuticals has entered the medical marijuana sector due to the growing acceptance by the public, all levels of governments and the revenue potential it can generate
John Adams, President of Easton Pharmaceuticals commented, "With thousands of people in the nearby state of Michigan and various Canadian provinces and jurisdictions to follow, requiring relief from various ailments and illnesses that only the use of medicinal marijuana can provide relief for, Easton has chosen to participate in this industry that has slowly over the last few years received recognition for its medicinal benefits. The United States congress was to have made a final decision approving the use of medical marijuana in limited ways, but recently adjourned the final decision for later in the year."
According to the Long Beach Business Journal in their article titled "The Business of Medical Marijuana" the medical cannabis industry alone was worth about 1.7 billion in 2011, according to a report by the financial news firm See Change Strategy. That figure could reach nearly $9 billion nationwide in five years, as the federal government in the United States clears the way for more states to likely legalize marijuana for medicinal purposes.
One of marijuana's greatest advantages as a medicine is its remarkable safety. It has little effect on major physiological functions. There is no known case of a lethal overdose. On the basis of animal models, the ratio of lethal to effective dose is estimated as 40,000 to 1. By comparison, the ratio is between 3 and 50 to 1 for secobarbital, and between 4 and 10 to 1 for ethanol. Marijuana is also far less addictive and far less subject to abuse than many drugs now used as muscle relaxants, hypnotics, and analgesics. The chief legitimate concern is the effect of smoking on the lungs. Cannabis smoke carries more tars and other particulate matter than tobacco smoke. But the amount smoked is much less, especially in medical use, and once marijuana is an openly recognized medicine, solutions may be found such as vaporization, tinctures, extracts and oils. At present, the greatest danger in medical use of marijuana is its illegality, which imposes much anxiety and expense on suffering people, forces them to bargain with illicit drug dealers, and exposes them to the threat of criminal prosecution.
About Easton Pharmaceuticals Inc
Toronto-based Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding number of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins, the world market for these conditions is in excess of $10 billion.
The company's updated proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals’ flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women’s sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.
For More Information Visit
http://www.ashleybiomedical.com & http://www.eastonpharma.com
Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing and other risks and uncertainties as stated in the company's financial reports and filings.
John Adams, President/CEO
Contact:
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Media and Investor Relations: info@ashleybiomedical.com, info@lamindustries.com
They have several Viable products that will soon be in stores around the world and new people who know how to do it with great backgrounds try doing some dd on the new managment
Nice day for EAPH up 11% such a low float and waiting on some Great news. This will explode on any news of revenue Starting Keep on close watch on it :)
Thats possible but they hold so few shares if you read there report and filings
lol wrong they have not sold stock for years maybe givin away stock for services that were sold but they have not dumped shares for years the shares outstanding have been within 35 million outstanding for years do some DD and see for yourself
LOL THERE IS NO FRAUD ON EAPH all pinks sell from time to time to raise money show me one that has not
There has been no pump and dump on this stock in a long time and the float is one of the lowest on any pink stock traded and in the best possible area PHARMACEUTICALS :)
No, There is no volume to account for that at all (yet ) ,the 30/35 million shares in the report to the account was all that was sold in my opinion Issued by old managment ,
There has not been much more than that, that has even traded since the new guys took over so no selling to account for dilution yet , Who knows about the future but for now this low float could fly if the new was good. One of the new guys is a money guy so let see where the funding comes from in the next quartly or news b4 crying dilution
No, I dont think so ,there were no more shares issued for any services by the old managment b4 they left
I think the 30 million shares the accountant got from old management is all sold now and we will see some good news anytime now. The selling looks to be over and with such a small float this could jump up real fast on little volume.
There was no co. dumping shares its was the accountant seling the millions of shares he got for services from the old managment The news guys are trying to make this work I think we will see some Positive news soon (imo)
thank you all I will see what I can do :)
can anyone tell me how big the wall is at 13 or 14 l2 maybe I can nock it down a little :)
whats it look like above that ?
ok thank you I took a small stake and will watch for now thanks again
on the road I want to buy in would like a L 2 quote first anyone please :) thank you